Acquisition significantly boosts EUSA Pharma’s presence as a global biopharmaceutical company in oncology and rare diseases SYLVANT is the only FDA and EMA approved treatment for the rare disorder, idiopathic multicentric Castlemen’s disease (iMCD) Leverages EUSA...
ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Ernst & Young (EY) named AxoGen Chairman and CEO Karen Zaderej as the Entrepreneur...
ALACHUA, Florida (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced today that it has priced an underwritten public offering of 3,000,000 shares of its common stock,...
MALVERN, Pennsylvania—Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved...
WATERTOWN, Massachusetts(GLOBE NEWSWIRE)—pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the acquisition of Icon Bioscience Inc. (Icon). Icon is a...
HEMEL HEMPSTEAD, England –– EUSA Pharma (EUSA), a world-class specialty pharmaceutical company focused on oncology and oncology supportive care, today announced the appointment of Rolf K Hoffmann to its Board of Directors. Mr Hoffmann is currently Chairman of Biotest...
NEW YORK, NY—Cota Inc., a healthcare real-world evidence and data analytics company bridging precision medicine to population health, today announced the completion of a Series C round of financing led by IQVIA (NYSE:IQV) with major participation by EW Healthcare...
ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that it has commenced an underwritten public offering of its common...
HEMEL HEMPSTEAD, England & CAMBRIDGE, Massachusetts. – – EUSA Pharma and AVEO Oncology (NASDAQ: AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland,...
